Adial pharmaceuticals, inc. (ADIL)
CashFlow / Yearly
Dec'18Dec'17
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss

-11,631

-1,139

Adjustments to reconcile net loss to net cash used in operating activities:
Equity-based compensation

5,368

205

Non-cash interest expense

776

-

Amortization of intangible assets

0

0

Amortization of debt discounts

352

102

Loss on debt extinguishments

-3,484

-

Changes in operating assets and liabilities:
Prepaid research and development expenses

505

-

Prepaid expenses and other current assets

308

-9

Note receivable – related party

-

0

Other assets

-

-2

Accounts payable

-190

324

Accrued expenses

155

-

Net cash used in operating activities

-2,498

-494

Proceeds from note receivable - related party

-

35

Net cash provided by investing activities

-

35

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of common stock and warrants

6,267

40

Proceeds from Senior Secured Bridge Note

-

250

Proceeds from Subordinated Notes Payable

-

100

Proceeds from Senior Note

275

-

Proceeds from Senior Secured Notes, including related party

410

-

Repayment of Senior Secured Bridge Note

150

-

Repayment of Senior Secured Notes, including related party

510

-

Repayment of Senior Secured Bridge Note

100

-

Proceeds from warrant exercise

156

-

Net cash provided by financing activities

6,349

390

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

3,850

-69

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid

38

-

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of warrants for financing costs classified as debt discount

222

-

Beneficial conversion discount on convertible notes payable

52

-

Exchange of Subordinated notes in the amount of $115,639 for Senior secured notes

100

-

Stock and warrants issued per terms of June 2018 notes and FirstFire note

3,747

-

Stock and warrants issued for MVA agreement

385

-

Stock and warrants issued for conversion of convertible notes

545

-

Stock issued on conversion of June 2018 note

325

-